TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05958628

Intervention type: OTHER
Group type: OTHER
Intervention: Conventional physiotherapy
Description: The treatment program was designed in line with the patients' compliance, functional capacities and rehabilitation goals as neurodevelopmental therapy based on the ability to adapt to change, reorganization and healing in the brain by focusing on neuroplasticity from neurodevelopmental treatment approaches; Proprioceptive neuromuscular facilitation techniques to increase selective and voluntary movement; functional exercises to increase motor control skills, stretching exercises for spasticity and neuromuscular electrical stimulation.~The control group received conventional physiotherapy exercises for 45 minutes and neuromuscular electrical stimulation for 15 minutes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional physiotherapy
Description: The treatment program was designed in line with the patients' compliance, functional capacities and rehabilitation goals as neurodevelopmental therapy based on the ability to adapt to change, reorganization and healing in the brain by focusing on neuroplasticity from neurodevelopmental treatment approaches; Proprioceptive neuromuscular facilitation techniques to increase selective and voluntary movement; functional exercises to increase motor control skills, stretching exercises for spasticity and neuromuscular electrical stimulation.~The control group received conventional physiotherapy exercises for 45 minutes and neuromuscular electrical stimulation for 15 minutes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Robotic Hand Exoskeleton System
Description: In the treatment applications with the robotic hand exoskeleton system, which is designed to accelerate the healing process of patients in need of hand rehabilitation, to gain motor skills, to provide strength training and to increase participation in treatment, the patient will be asked to allow the system to move the hand at adjusted angles for 10 minutes and to accompany this movement. In the applications, while the patient is sitting comfortably and safely, the patient will be asked to place the stroke-affected hand into the system. The hand of patients who may have difficulty due to the functional status of the upper extremity and the severity of spasticity will be placed with the help of the physiotherapist. The physiotherapist will be with the patient throughout the application.
Study: NCT05608915

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No Cue
Description: There will be no visual cues at all. Will be tested off-medication (after holding morning dopaminergic medications).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional Cue
Description: Physical lines taped to floor at regular intervals. Will be tested off-medication (after holding morning dopaminergic medications).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Constant Cue
Description: The augmented-reality visual cue will always be turned on. Will be tested off-medication (after holding morning dopaminergic medications).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient hand-triggered
Description: The augmented-reality visual cue will be turned on, intermittently, each time the patient clicks a handheld button. Will be tested off-medication (after holding morning dopaminergic medications).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient eye-triggered
Description: The augmented-reality visual cue will be turned on, intermittently, each time the patient looks down at the floor near their feet. Will be tested off-medication (after holding morning dopaminergic medications).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Examiner-triggered
Description: The augmented-reality visual cue will be turned on, intermittently, by an examiner, whenever they feel the patient is having a freezing episode or at risk of having a freezing episode. Will be tested off-medication (after holding morning dopaminergic medications).
Study: NCT06194240

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DiabACT
Description: E-program proposed to diabetic patients based on ACT therapy.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DiabACT
Description: E-program proposed to diabetic patients based on ACT therapy.
Study: NCT05783440

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: direct patient feedback
Description: Participants in the intervention group report postoperative pain scores and other pain related outcomes with their own smartphone. Pain scores reported by smartphone \> 3 (NRS 0-10) are immediately passed on to the nurse who will receive a notification on a smartphone.~All patient reported pain-scores by smartphone are stored in a database that is not accessible to medical or nursing staff from the nursing ward.
Study: NCT04237662

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Root Instrumentation
Description: Instrumentation of the root surface in order to achieve debridement

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Root Instrumentation
Description: Instrumentation of the root surface in order to achieve debridement

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Enamel Matrix Derivative application
Description: Enamel Matrix Derivative will be applied in the sites with at least 6 mm of pocket depths
Study: NCT05996458

Intervention type: OTHER
Intervention: Gastroenteroscopy；Risk factor investigation; FIT-HP;RNF180 and SEPTIN9 gene methylation test
Description: group one: The screening population will undergo gastroscopy, colonoscopy, fecal occult blood test (FIT), Helicobacter pylori (HP) antigen test, RNF180/Septin9 gene methylation test, and investigation of risk factors, including past disease history, alcohol drinking history, smoking history, tea drinking history, family history of cancer, marital and reproductive status, and dietary habits.

Intervention type: OTHER
Intervention: Risk factor investigation;
Description: Only the risk factors will be investigated, including previous disease history, drinking history, smoking history, drinking history, family history of malignant tumor, marriage and childbearing status, eating habits, etc.

Intervention type: OTHER
Intervention: Risk factor investigation;
Description: Only the risk factors will be investigated, including previous disease history, drinking history, smoking history, drinking history, family history of malignant tumor, marriage and childbearing status, eating habits, etc.

Intervention type: OTHER
Intervention: Gastroenteroscopy；Risk factor investigation; FIT-HP;RNF180 and SEPTIN9 gene methylation test
Description: group two: The screening population will undergo investigation of risk factors, a fecal occult blood test (FIT), and a stool test for Helicobacter pylori (HP) antigen. If a stool occult blood test or H. pylori antigen is positive after testing, RNF180 and SEPTIN9 gene methylation testing will be scheduled. If the gene methylation test is positive, a colonoscopy will be scheduled.
Study: NCT05910502

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Autism Family Empowerment Coaching and Training Program
Description: Participants in the intervention group will be connected with Project AFECT Coaches who will provide: Coaching to (1) assure parents understand diagnosis, (2) assist parents in finding accurate, current information about autism, (3) guide parents to free online autism training resources, (4) empower parents to evaluate child's intervention plan holistically, and (5) provide emotional support to reduce stress; Navigation to (1) help family access autism treatments, and (2) connect to early intervention and educational services.
Study: NCT05360290

Intervention type: DEVICE
Group type: OTHER
Intervention: GILUPI CellCollector®
Description: Use of GILUPI CellCollector® to detect CTC

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: GILUPI CellCollector®
Description: Use of GILUPI CellCollector® to detect CTC
Study: NCT06170983

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin
Description: 500 mg once daily for 3 days
Study: NCT04517266

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: omit of IMI group
Description: clincial high risk breast （≥2 risk factors）patients with 18-gene low risk an indication for regional nodal irradiation will received 2 Gy for 25 fractions to chest wall or whole breast and supraclavicular lymph nodes irradiation and sequential tumor bed boost of 2 Gy for 5 fractions following breast conserving surgery.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: IMI group
Description: clincial high risk breast （≥2 risk factors）patients with 18-gene low risk an indication for regional nodal irradiation will received 2 Gy for 25 fractions to chest wall or whole breast and supraclavicular lymph nodes irradiation and sequential tumor bed boost of 2 Gy for 5 fractions following breast conserving surgery.
Study: NCT05216094

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: smart phone App
Description: stroke subjects completed tasks-oriented program demoed in the smart phone app with affected upper limb or bilateral arm movement for 12 weeks

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conventional rehabilitation
Description: stroke subjects receive conventional rehabilitation home program with smart phone app ,without task-oriented program demoed function, for 12 weeks
Study: NCT05153980

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Warm-up + Blood Flow Restriction cuff (smart-cuff pro device, acting as pressurized tourniquet)
Description: Blood Flow Restriction

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Warm-up
Description: Warm-up without any special intervention (no Blood Flow Restriction)
Study: NCT04663152

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: INSTACARE
Description: CHWs will provide participants with support via phone calls, home-visits, and accompaniment to clinic visits to improve medication management and HIV viral suppression. CHWs will contact participants at least once per week for three months.
Study: NCT06129669

Intervention type: DRUG
Intervention: Indocyanine green
Description: Administration of ICG during surgery and recording of the fluorescence video to perform data analyses

Intervention type: DRUG
Intervention: Indocyanine green
Description: Administration of ICG during surgery and recording of the fluorescence video to perform data analyses

Intervention type: DRUG
Intervention: Indocyanine green
Description: Administration of ICG during surgery and recording of the fluorescence video to perform data analyses

Intervention type: DRUG
Intervention: Indocyanine green
Description: Administration of ICG during surgery and recording of the fluorescence video to perform data analyses

Intervention type: DRUG
Intervention: Indocyanine green
Description: Administration of ICG during surgery and recording of the fluorescence video to perform data analyses

Intervention type: DRUG
Intervention: Indocyanine green
Description: Administration of ICG during surgery and recording of the fluorescence video to perform data analyses

Intervention type: DRUG
Intervention: Indocyanine green
Description: Administration of ICG during surgery and recording of the fluorescence video to perform data analyses

Intervention type: DRUG
Intervention: Indocyanine green
Description: Administration of ICG during surgery and recording of the fluorescence video to perform data analyses
Study: NCT06068413

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CT image-assisted detection software
Description: CT image-assisted detection software can help doctor to diagnosis the focal liver lesion
Study: NCT06503211

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: UTAA09 injection
Description: The subjects, who sign the informed consent forms and been screeneinclusion/exclusion criteria, will be assigned into 3 x 108\~1 x 1010 CD19-CAR - γδT cells.
Study: NCT06015321

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: enzalutamide 160 mg PO daily
Study: NCT05093231

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab is a highly selective immunoglobulin G4-kappa humanised monoclonal antibody against Programmed cell death protein 1 (PD-1) receptor. It was generated by grafting the variable sequences of a very high-affinity mouse antihuman PD-1 antibody onto a human IgG4-kappa isotype with the containing a stabilizing Serine 228 to Proline Fc mutation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Olaparib is a potent inhibitor of polyadenosine 5'diphosphoribose polymerase (PARP) developed as a monotherapy as well as for combination with chemotherapy, ionising radiation and other anti-cancer agents including novel agents and immunotherapy.
Study: NCT06170983

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin
Description: 500 mg once daily for 3 days

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Skin punch biopsy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Skin inflammation model
Description: LPS- or imiquimod induced skin inflammation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Skin inflammation model
Description: LPS- or imiquimod induced skin inflammation
Study: NCT04765540

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low Intensity Nudges
Description: A bundle of 'low-intensity' passive interventions, including:~Large Mirrors \& hand-shaped sign posts pointing to the station

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High Intensity Activities
Description: A bundle of 'high-intensity' active interventions delivered for three weeks, including:~Free soap and free facemasks for handwashing station users, a community message board \& general encouragement

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: BRAC's business-as-usual
Description: A set of community activities to increase awareness of public handwashing stations and the need to use them. This includes in-person group sessions demonstrating hand hygiene as well as stickers and posters placed in the community to alert people to the handwashing stations.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BRAC's business-as-usual
Description: A set of community activities to increase awareness of public handwashing stations and the need to use them. This includes in-person group sessions demonstrating hand hygiene as well as stickers and posters placed in the community to alert people to the handwashing stations.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BRAC's business-as-usual
Description: A set of community activities to increase awareness of public handwashing stations and the need to use them. This includes in-person group sessions demonstrating hand hygiene as well as stickers and posters placed in the community to alert people to the handwashing stations.
Study: NCT04669496

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neoadjuvant treatment
Description: PD1 antibody (Toripalimab) combined with GEMOX chemotherapy and Lenvatinib neoadjuvant treatment
Study: NCT05415735

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stress Management and Resiliency Training Program
Description: This is a multimodal mind-body program designed to teach participants a variety of different strategies to reduce their physiologic stress response.
Study: NCT05189730

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirelizumab
Description: Two cycles of Tirelizumab (200mg administered as an intravenous infusion over 30 minutes per 3 weeks), D1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Two cycles of paclitaxel (135mg/m2 administered as an intravenous infusion per 3 weeks), D1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Two cycles of carboplatin(AUC=5 administered as an intravenous infusion per 3 weeks) D1.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Neoadiuvant radiotherapy
Description: Simultaneous radiotherapy would be consecutively performed for 4 weeks with the total dose of 40Gy (40Gy/ 4W /20F), D1.
Study: NCT04982900

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: furmonertinib
Description: AST2818 is an irreversible and highly selective EGFR inhibitor independently discovered and developed by Allist. It has the potential to become the best-in-class drug in the third-generation EGFR-TKIs. Data from the preclinical studies and the completed clinical studies show that AST2818 has the following advantages: 1) AST2818 has good target selectivity and tissue distribution specificity; 2) The objective response rate of AST2818 for the patients with locally advanced or metastatic NSCLC with EGFR T790M mutation is outstanding, reaching 74.1% in the key registration clinical study; 3) AST2818 has a good safety profile and is well-tolerated; 4) AST2818 and its active metabolites have a superior ability to penetrate the blood-brain barrier, and have a good therapeutic efficacy on brain metastases frequently seen in patients with NSCLC.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo has the same appearance, weight, and physical and chemical properties as the study drug, and is provided by the researcher to the subjects in control group.
Study: NCT06342999

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fetal Aortic Valvuloplasty Procedure
Description: Treatment given during pregnancy in which a balloon is used to increase the size of the baby's aortic valve in vitro.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Emerge Monorail and Over-The-Wire PTCA Dilatation Catheter
Description: Balloon Catheter
Study: NCT06509464

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High intensity interval training
Description: High intensity interval training on treadmill
Study: NCT06342999

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Trek RX and Mini Trek RX Coronary Dilatation Catheter
Description: Coronary Dilation Catheter
Study: NCT05587361

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propranolol
Description: Propranolol Capsule; 40 mg IR

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propranolol
Description: Propranolol Capsule; 40 mg IR

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine Patch
Description: Nicotine Patch; 14 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine Patch
Description: Nicotine Patch; 14 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Propranolol
Description: Placebo Capsule, no active ingredients

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Propranolol
Description: Placebo Capsule, no active ingredients

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Patch
Description: Placebo Patch, no active ingredients

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Patch
Description: Placebo Patch, no active ingredients
Study: NCT04701073

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LombaStab belt
Description: Instruction given to the patient will be to wear the LombaStab belt from 4 to 8 hours per days, over the whole duration of the study (12 weeks). The investigator will explain to the patient how to adjust it.~The LombaStab belt will be equiped with thermosensor to evaluate the belt wearing time at the end of the study.
Study: NCT05024396

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: maximum jump height
Description: Three single leg countermovement jumps were performed. The maximum jump height is measured with a sensor that is adapted at the subjects'leg and with a force plate.
Study: NCT05374421

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Erchonia® THL™
Description: The Erchonia® THL™ is made up of (2) 405-nanometer violet laser diodes mounted in a portable handheld device. The diodes are positioned approximately 4 inches from the skin and applied in a continuous back and forth sweeping motion from the top of the ear down the side of the neck. The treatments will be self-administered by the subject at his or her's place of residence, once per day for 28 days. Each procedure administration lasts 5 minutes per ear, for a total of 10 minutes.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Laser
Description: The Placebo Laser has the same appearance as the Erchonia® THL™ but does not emit any therapeutic light. The diodes are positioned approximately 4 inches from the skin and applied in a continuous back and forth sweeping motion from the top of the ear down the side of the neck. The treatments will be self-administered by the subject at his or her's place of residence, once per day for 28 days. Each procedure administration lasts 5 minutes per ear, for a total of 10 minutes.
Study: NCT06404905

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BT02 monoclonal antibody injection
Description: It is expected to include 10-30 patients assigned to dose escalation cohorts.
Study: NCT05833867

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sacituzumab govitecan
Description: 8 mg/kg Sacituzumab Govitecan is to be administered intravenously in 21-day cycles on Day 1 and Day 8; the next cycle should start a minimum of 14 days after the Day 8 dose (i.e., the Day 8 infusion will be counted as the first day of that 14-day period).

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Adaptive Radiotherapy
Description: Concurrently, participants will receive an individualized tailored plan for radiation therapy.
Study: NCT06141031

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TTI-101
Description: TTI-101 is an orally bioavailable, small-molecule inhibitor of Signal Transducer and Activator of Transcription 3 (STAT3), a transcription factor whose upregulation and activation governs many hallmarks of cancer, inflammation, and fibrosis.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TTI-101
Description: TTI-101 is an orally bioavailable, small-molecule inhibitor of Signal Transducer and Activator of Transcription 3 (STAT3), a transcription factor whose upregulation and activation governs many hallmarks of cancer, inflammation, and fibrosis.
Study: NCT06153173

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirdametinib
Description: Mirdametinib is administered at a dose of 2 mg/m2, twice a day (BID) with a maximum dose of 4 mg BID on a continuous daily schedule. Consecutive doses should be separated by minimum 6 hours and maximum 14 hours.
Study: NCT05598333

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AB-1002
Description: Intracoronary Infusion of AB-1002 or placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AB-1002
Description: Intracoronary Infusion of AB-1002 or placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: AB-1002
Description: Intracoronary Infusion of AB-1002 or placebo